Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
25 11 2019
Historique:
received: 29 05 2019
accepted: 29 10 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 10 3 2020
Statut: epublish

Résumé

DNA base editors have enabled genome editing without generating DNA double strand breaks. The applications of this technology have been reported in a variety of animal and plant systems, however, their editing specificity in human stem cells has not been studied by unbiased genome-wide analysis. Here we investigate the fidelity of cytidine deaminase-mediated base editing in human induced pluripotent stem cells (iPSCs) by whole genome sequencing after sustained or transient base editor expression. While base-edited iPSC clones without significant off-target modifications are identified, this study also reveals the potential of APOBEC-based base editors in inducing unintended point mutations outside of likely in silico-predicted CRISPR-Cas9 off-targets. The majority of the off-target mutations are C:G->T:A transitions or C:G->G:C transversions enriched for the APOBEC mutagenesis signature. These results demonstrate that cytosine base editor-mediated editing may result in unintended genetic modifications with distinct patterns from that of the conventional CRISPR-Cas nucleases.

Identifiants

pubmed: 31767844
doi: 10.1038/s41467-019-13342-8
pii: 10.1038/s41467-019-13342-8
pmc: PMC6877639
doi:

Substances chimiques

Cytosine 8J337D1HZY
APOBEC Deaminases EC 3.5.4.5
Cytidine Deaminase EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5353

Subventions

Organisme : NICHD NIH HHS
ID : R03 HD091264
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB023812
Pays : United States

Références

Nat Genet. 2013 Sep;45(9):970-6
pubmed: 23852170
Genome Biol. 2016 Jul 05;17(1):148
pubmed: 27380939
BMC Biol. 2018 Dec 28;16(1):150
pubmed: 30593278
Sci Adv. 2017 Aug 30;3(8):eaao4774
pubmed: 28875174
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5
pubmed: 21586637
Nat Biotechnol. 2018 Oct;36(9):843-846
pubmed: 29813047
Nat Methods. 2016 Dec;13(12):1029-1035
pubmed: 27723754
Nature. 2019 May;569(7756):433-437
pubmed: 30995674
Nucleic Acids Res. 2018 Aug 21;46(14):e84
pubmed: 29746667
Science. 2016 Sep 16;353(6305):
pubmed: 27492474
Nat Biotechnol. 2017 May;35(5):475-480
pubmed: 28398345
Nat Commun. 2018 Nov 15;9(1):4804
pubmed: 30442934
Genome Biol. 2014 Jul 31;15(7):417
pubmed: 25085003
Nat Commun. 2019 Jan 8;10(1):67
pubmed: 30622278
Mutat Res. 2017 Dec;824:1-8
pubmed: 29150045
Nat Methods. 2016 Dec;13(12):1036-1042
pubmed: 27798611
Nat Biotechnol. 2019 Sep;37(9):1041-1048
pubmed: 31477922
Nat Biotechnol. 2018 Oct;36(9):888-893
pubmed: 29969439
Bioinformatics. 2014 May 15;30(10):1473-5
pubmed: 24463181
FASEB J. 2019 Aug;33(8):9210-9219
pubmed: 31071267
Cell Stem Cell. 2012 Mar 2;10(3):337-44
pubmed: 22385660
Mol Cell. 2002 Nov;10(5):1247-53
pubmed: 12453430
Nat Commun. 2017 May 09;8:15183
pubmed: 28485371
Nat Biotechnol. 2018 Oct 01;:
pubmed: 30272679
Stem Cells Dev. 2012 Aug 10;21(12):2298-311
pubmed: 22225458
Nat Biotechnol. 2018 Nov;36(10):946-949
pubmed: 30125268
Nat Biotechnol. 2019 Apr;37(4):430-435
pubmed: 30833658
Mutat Res Genet Toxicol Environ Mutagen. 2018 May - Jun;829-830:61-69
pubmed: 29704995
Sci Adv. 2019 May 08;5(5):eaax5717
pubmed: 31086823
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Nat Protoc. 2012 Nov;7(11):2013-21
pubmed: 23080273
Nucleic Acids Res. 2016 Jul 8;44(W1):W272-6
pubmed: 27185894
Nat Commun. 2017 Jun 06;8:15790
pubmed: 28585549
Nat Biotechnol. 2019 Sep;37(9):1070-1079
pubmed: 31332326
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W401-7
pubmed: 24861617
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Nat Biotechnol. 2018 Nov;36(10):977-982
pubmed: 30059493
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Nat Biotechnol. 2019 Jun;37(6):626-631
pubmed: 31110355
Nat Biotechnol. 2017 Apr;35(4):371-376
pubmed: 28191901
Science. 2019 Apr 19;364(6437):292-295
pubmed: 30819931
PLoS One. 2016 May 10;11(5):e0155391
pubmed: 27163364
Nature. 2019 Jul;571(7764):275-278
pubmed: 31181567
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Genet. 2013 Sep;45(9):977-83
pubmed: 23852168
Cell Stem Cell. 2014 Jul 3;15(1):12-3
pubmed: 24996165
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1531-6
pubmed: 21205896
Science. 2019 Apr 19;364(6437):289-292
pubmed: 30819928
Bioinformatics. 2015 Sep 15;31(18):3078-80
pubmed: 25979474

Auteurs

Erica McGrath (E)

Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Hyunsu Shin (H)

Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Linyi Zhang (L)

Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Je-Nie Phue (JN)

Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Wells W Wu (WW)

Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Rong-Fong Shen (RF)

Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Yoon-Young Jang (YY)

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Javier Revollo (J)

Division of Genetic and Molecular Toxicology, National Center for Toxicology Research, Food and Drug Administration, Jefferson, AR, USA. Javier.Revollo@fda.hhs.gov.

Zhaohui Ye (Z)

Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Zhaohui.Ye@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH